Compare NRDY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDY | FATE |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 125.6M |
| IPO Year | 2020 | 2013 |
| Metric | NRDY | FATE |
|---|---|---|
| Price | $10.33 | $2.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.00 | ★ $4.10 |
| AVG Volume (30 Days) | 421.5K | ★ 1.7M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.16 | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | $4.88 | N/A |
| Revenue Next Year | $10.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.93 |
| 52 Week High | $11.03 | $3.23 |
| Indicator | NRDY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 92.92 | 47.44 |
| Support Level | $0.83 | $1.01 |
| Resistance Level | N/A | $2.88 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | 1.12 | -0.02 |
| Stochastic Oscillator | 92.44 | 40.00 |
Nerdy Inc operate a next-generation live tutoring and intervention platform that leverages the power of human expertise with Developed artificial intelligence (AI) to personalize learning, accelerate student achievement, and empower educators. The company's proprietary platform leverages technology, including AI, to connect learners with instructors across a wide range of subjects and formats, including subscription-based learning, one-on-one instruction, small group tutoring, large-format classes, and assessments. Its flagship business operates under the Varsity Tutors brand. The company's offerings are available directly to students and consumers, as well as through schools and other institutions.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.